Yumanity Therapeutics (FRA:8IY) Asset Impairment Charge : €3.54 Mil (TTM As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics Asset Impairment Charge?

Yumanity Therapeutics's Asset Impairment Charge for the three months ended in Sep. 2022 was €0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2022 was €3.54 Mil.

Yumanity Therapeutics Asset Impairment Charge Historical Data

The historical data trend for Yumanity Therapeutics's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics Asset Impairment Charge Chart

Yumanity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Asset Impairment Charge

Yumanity Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Asset Impairment Charge	Get a 7-Day Free Trial							-	-	3.54	-	-

Yumanity Therapeutics Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.54 Mil.

Yumanity Therapeutics Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Yumanity Therapeutics's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Yumanity Therapeutics (FRA:8IY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (FRA:8IY) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

40 Guest Street, Suite 4410, Boston, MA, USA, 02135

Website

https://www.yumanity.com

Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Yumanity Therapeutics (FRA:8IY) Headlines

No Headlines